Janux Therapeutics (NASDAQ:JANX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Janux Therapeutics (NASDAQ:JANX) from a sell rating to a hold rating in a research note issued to investors on Sunday morning.

A number of other brokerages have also commented on JANX. Cantor Fitzgerald decreased their target price on Janux Therapeutics from $150.00 to $100.00 and set an “overweight” rating for the company in a research report on Friday, February 27th. Barclays decreased their target price on Janux Therapeutics from $48.00 to $29.00 and set an “overweight” rating for the company in a research report on Wednesday, December 17th. Guggenheim decreased their target price on Janux Therapeutics from $72.00 to $68.00 and set a “buy” rating for the company in a research report on Friday, February 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Janux Therapeutics in a research report on Thursday, January 22nd. Finally, Clear Str lowered Janux Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 20th. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Janux Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $56.91.

Janux Therapeutics Trading Down 0.1%

JANX stock opened at $14.93 on Friday. The stock has a 50-day moving average price of $13.71 and a 200-day moving average price of $18.79. Janux Therapeutics has a 1-year low of $12.12 and a 1-year high of $35.34. The firm has a market cap of $908.19 million, a PE ratio of -8.16 and a beta of 2.82.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.14. The business had revenue of $7.88 million during the quarter, compared to the consensus estimate of $0.08 million. On average, analysts forecast that Janux Therapeutics will post -1.38 earnings per share for the current year.

Institutional Trading of Janux Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Janux Therapeutics in the 4th quarter worth approximately $34,000. Osaic Holdings Inc. boosted its stake in shares of Janux Therapeutics by 704.6% in the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after buying an additional 3,037 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of Janux Therapeutics in the 4th quarter worth approximately $51,000. Tower Research Capital LLC TRC boosted its stake in shares of Janux Therapeutics by 175.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock worth $91,000 after buying an additional 2,502 shares during the last quarter. Finally, Winthrop Capital Management LLC purchased a new position in shares of Janux Therapeutics in the 3rd quarter worth approximately $106,000. 75.39% of the stock is owned by institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.